Santé log

Trained Therapeutix Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC ...

RIDE-001 was developed using Trained Therapeutix’s proprietary ApoA1-based nanomedicines platform to target the bone marrow where it activates the intracellular pattern recognition receptor NOD2. This ...
Santé log

Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide

Only 30% of patients who start GLP-1s for weight loss are still using them after one year, with GI side effects cited as the #1 cause of treatment discontinuation NG101 is a first-in-class therapy ...
Santé log

Wave Life Sciences to Present at Upcoming Investor Conferences

Live webcasts of the analyst-led fireside chats can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: ...
Santé log

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement. Pemvidutide demonstrated signifi ...
Santé log

Precision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots

Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of ...
Santé log

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in ...
Santé log

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

(Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City featuring ...
Santé log

Treace Announces Participation in Two Upcoming Investor Conferences

Internet Posting of Information Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages ...
Santé log

Celldex to Present at Upcoming Investor Conferences

Live webcasts of the presentations will be available on the " Events & Presentations " page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event ...
Santé log

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

In mice bearing poorly immunogenic EMT6 tumors, a sequential regimen of mWTX-330 (IL-12) followed by WTX-124 (IL-2) was well tolerated and demonstrated superior tumor-killing ability compared to ...
Santé log

Flare Therapeutics Presents Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at SITC 2025 40th Anniversary Annual Meeting

Demonstrates PPARG inhibition as a potential strategy to overcome immune resistance in advanced UC − Supports the planned Phase 1 cohort of FX-909 in combination with pembrolizumab; initiating in the ...
Santé log

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune disorders, today announced the ...